Clinical trials: Inflammatory Biomarkers
Colitis, Ulcerative
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
This study represents the first investigation of anrukinzumab in patients with active ulcerative colitis (UC) and will evaluate proof of mechanism by changes in the mechanism based biomarker (YKL 40) and pharmacodynamic…
- Trial name
- NCT01284062
- Testing
- Anrukinzumab
- Where
- 76 sites in United States, Austria and 9 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Sickle Cell Disease
Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Background: Sickle cell disease (SCD) is an inherited hemoglobin disorder. People with SCD have an increased chance for getting blood clots.
- Trial name
- NCT04514510
- Testing
- Isoquercetin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Coronary Artery Disease
Anti-inflammatory Effects of Colchicine in PCI
Peri-procedural inflammation is associated with increased rates of post-procedural myocardial infarction (MI), which occur in up to 35% of PCI patients and are themselves associated with increased risk of later MI and death.
- Trial name
- NCT01709981
- Testing
- Colchicine
- Where
- 3 sites in United States
- Volunteers
- 280 people
- Sponsor
- NYU Langone Health
Bloodstream Infections, Short Bowel Syndrome
Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants
The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome.
- Conditions
- Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition
- Trial name
- NCT01576003
- Testing
- Glutamine, L-alanine
- Where
- 2 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.
Hemophagocytic Lymphohistiocytosis
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.
- Trial name
- NCT03259230
- Testing
- Blood Draws, Data Collection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Swedish Orphan Biovitrum
Stroke, Acute
Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
- Trial name
- MINOS (NCT00630396)
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- David Hess, MD
Human Microbiome
Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation
Normal aging can lead to loss of gut microbial biodiversity which is linked to inflammaging and immunosenescence or the loss of immunocompetence.
- Trial name
- TRIPH2017 (NCT03907501)
- Testing
- Synbiotic, Probiotic
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego